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Abstract
NRF2/ARE signaling pathway is a principal regulator of cellular redox homoeostasis. The stress-induced transcription
factor, NRF2, can shield cells from the oxidative damages via binding to the consensus antioxidant-responsive element
(ARE) and driving several cyto-protective genes expression. Increasing evidence indicated that aberrant activation of
NRF2 in malignant cells may support their survival through various pathways to detoxify chemotherapy drugs, attenuate
drug-induced oxidative stress, or induce drug efﬂux, all of which are crucial in developing drug resistance. Accordingly,
NRF2 is a potential drug target for improving the effectiveness of chemotherapy and to reverse drug resistance in cancer
cells. A stable ARE-driven reporter human head and neck squamous cell carcinoma (HNSCC) cell line, HSC3-ARE9, was
established and utilized to screen novel NRF2 inhibitors from a compound library. The cotton plant derived phenolic
aldehyde-gossypol was selected for further analyses. The effects of gossypol in cancer cells were determined by western
blotting, RT-qPCR, clonogenic assay, and cell viability assays. The gossypol-responsive gene expression levels were
assessed in the Oncomine database. The effects of gossypol on conferring chemo-sensitization were evaluated in etoposide-resistant and cisplatin-resistant cancer cells. Our study is the ﬁrst to identify that gossypol is effective to reduce
both basal and NRF2 activator tert-butylhydroquinone (t-BHQ)-induced ARE-luciferase activity. Gossypol diminishes
NRF2 protein stability and thereby leads to the suppression of NRF2/ARE pathway, which resulted in decreasing the
expression levels of NRF2 downstream genes in both time- and dose-dependent manners. Inhibition of NRF2 by
gossypol signiﬁcantly decreases cell viabilities in human cancer cells. In addition, we ﬁnd that gossypol re-sensitizes
topoisomerase II poison treatment in etoposide-resistant cancer cells via suppression of NRF2/ABCC1 axis. Moreover,
gossypol suppresses NRF2-mediated G6PD expression thereby leads to induce synthetic lethality with cisplatin not only
in parental cancer cells but also in cisplatin-resistant cancer cells. These ﬁndings suggest that gossypol is a novel NRF2/
ARE inhibitor, and can be a potential adjuvant chemotherapeutic agent for treatment of chemo-refractory tumor.
Keywords: Cancer therapy, Chemo-resistance, Gossypol, NRF2 inhibitor

1. Introduction

N

uclear factor erythroid 2-related factor 2
(NRF2) is a transcription factor, which belongs
to basic leucine zipper (bZIP) family, and drives the

antioxidant response elements (ARE)-containing
genes [1]. Interaction with Kelch-like ECH-associated protein 1 (KEAP1), a substrate of Cullin 3-based
E3 ubiquitin ligase complex, results in impairing
transcriptional activity of NRF2 through inducing
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proteasomal degradation of NRF2 and then suppressing its nuclear translocation [2]. An uncontrolled over-activation of NRF2/ARE pathway has
been viewed as a crucially tumor-promoting factor
due to providing several advantages for cancel calls,
such as maintaining excessive proliferative
signaling, repressing the inhibitors of cell-cycle
progression, modulating cancer cell metabolism, and
increasing tolerance to excess reactive oxygen species (ROS) [3]. The crucial roles of persistent NRF2
activation in therapy resistance in cancers have been
well established [4,5]. Over-activation of NRF2 induces the expressions of drug-metabolizing enzymes, drug efﬂux transporters and the proteins
involved in redox homeostasis, subsequently offering protective effects to cancer cells against chemotherapy [4e6]. For instance, we previously identiﬁed
that NRF2-induced over-expression of multidrug
resistance-associated protein 1 (MRP1/ABCC1) and
aldo-keto reductase family 1C (AKR1C) enzymes
resulted in developing acquired resistance to topoisomerase II poisons and platinum drugs of cancer
cells [7,8]. Hence, these ﬁndings provide strong evidence that inhibition of NRF2 is a potent therapeutic
strategy for effective eradication of cancer [6].
Although no NRF2-targeted agents have been
approved by FDA for cancer therapy so far, several
promising strategies have been reported for inhibition of NRF2/ARE pathway; for instance, reducing
expression, promoting degradation, impairing
transcriptional activity, and suppressing nuclear
translocation of NRF2 [9]. Several naturally occurring substances, such as brusatol, luteolin, wogonin,
chrysin, convallatoxin, and procyanidins, have been
reported to inhibit NRF2 signaling pathway through
decreasing the mRNA or protein levels of NRF2, or
promoting the degradation of NRF2 protein [9,10].
Through a high-throughput screening system,
Bollong et al. identiﬁed a small molecule, AEM1,
which has the ability to reduce transcriptional activity of NRF2, thereby suppressing the expression
of NRF2-regulated genes [11]. Similarly, Singh et al.,
screened approximately 400,000 small molecules
from the Molecular Libraries Small Molecule Repository (MLSMR) by using a cell-based quantitative high-throughput screening system [12]. They
discovered a small molecule, ML385, which directly
interacts with the Neh1 domain of NRF2 and then
blocks the binding of the NRF2-MAFG complex to
the ARE sequence. These NRF2 inhibitors have
obvious cytotoxic activity against different types of
cancer cells. However, the problems of solubility,
speciﬁcity, and anti-cancer efﬁcacy in vivo have led
to the fact that currently available anti-NRF2 agents
are far from successfully translated into clinical
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applications. Therefore, there is still a need to
develop new NRF2 inhibitors.
In order to effectively and speciﬁcally identify
novel NRF2/ARE inhibitors, we used the AREdriven reporter cell system to screen 84 compounds
from the SCREEN-WELL® REDOX Library, and
identiﬁed gossypol as a new and effective NRF2/
ARE inhibitor. The anti-cancer cytotoxic and chemosensitization effect of gossypol were observed
through targeting NRF2/ARE pathway, suggesting
that development of effective and speciﬁc NRF2 inhibitors provides a new opportunity for cancer
therapy, particularly in chemo-refractory tumors.

2. Materials and methods
2.1. Cell culture
Human head and neck squamous cell carcinoma
(HNSCC) cell lines, including TW 2.6, SCC-15, and
HSC-3, were obtained and cultured as described
previously [13]. The human lung carcinoma cell line,
NCIeH460, was purchased from the American Type
Culture Collection (ATCC, VA, USA) and followed
the recommendations of the ATCC ofﬁcial website for
cell culture. KB-derived etoposide-resistant cell line
(KB-7D) [8] and HONE-1-derived cisplatin resistant
cell lines (cis6 and cis15) were established from
parental cancer cells by exposure to increasing concentrations of chemotherapeutic agents, such as etoposide (for establishment of KB-7D from KB cells) or
cisplatin (for establishment of cis6 and cis15 from
HONE-1 cells). When these drug-resistant cells grow
stably in high concentrations of chemotherapy drugs,
the individual clones were isolated and characterized.
All cell lines were kept in the humidiﬁed 37  C incubator with atmosphere of 95% air and 5% CO2.
2.2. Cell-based ARE-driven reporter and MTT
assay
A stable ARE-driven reporter human HNSCC cell
line, HSC3-ARE9, was generated previously by our
group [14]. For compound screening, the HSC3ARE9 cells were seeded at a density of
2.5  104 cells/well in 100 mL of culture medium in
96-well plates. After overnight incubation, the cells
were treated with 25 mM of the various compounds
from the SCREEN-WELL® REDOX Library (BML2835, Enzo Life Sciences, Farminedale, USA) for
24 h. The luciferase activity was measured by
Steady-Glo® Luciferase Assay System (E2520,
Promega, Madison, USA) according to the manufacturer's instructions. In order to exclude potential
compounds that may interfere with luciferase
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activity due to cytotoxicity, we analyzed the cell
viability under the same conditions as the AREdriven reporter analysis. In brief, 2.5  104 cells were
seeded in 96-well plates for overnight, and treated
with 25 mM of the test compounds for 24 h. At the
end of experiment, the cells were incubated with a
serum-free medium containing MTT at a ﬁnal concentration of 0.5 mg/ml for 4 h. The conversion of
MTT to formazan by metabolically viable cells was
assessed using 50% DMF solution containing 20%
SDS at 37  C overnight, and absorbance was
measured at 570 nm.

qPCR) by using gene-speciﬁc primers (Table S2), as
described previously [13]. The changes of NRF2,
NQO1, HO1, AKR1C1, AKR1C2, AKR1C3 and
PRDX1 mRNA levels were expressed as fold to
control after normalization to RPLP0.

2.3. Methylene blue assay

3. Results

(1) Cell viability assay: cells were seeded in 24well plates at a density of at a density of 8000 cells/
well for overnight, then cells were treated with
various concentrations of gossypol for the indicated
times. Cell viability was examined by performing
methylene blue assay [13]. (2) Clonogenic assay:
cells were seeded at a density of 200 cells/well in
2 mL of culture medium in 6-well plates for overnight, then cells were treated with various concentrations of gossypol. After 24-h incubation, the
gossypol-containing medium was replaced with
fresh, drug-free culture medium. And then cells
were incubated for 10 days to form colonies. The
colonies were visualized by staining with 0.5%
methylene blue for 2 h and the number of colonies
in each group was counted.

3.1. Screening of novel NRF2 inhibitors by using
stable ARE-driven reporter cell line, HSC3-ARE9

2.4. Western blot analysis
The cells were lysed and the protein extracts were
analyzed by performing western blotting as described
previously [13]. All primary antibodies were used at
dilutions of 1:500e2000 and listed in Table S1.
2.5. RNA extraction and real-time PCR
Total RNA was isolated from the cells and was
analyzed by performing real-time RT-PCR (RT-

2.6. Statistical analysis
Data was expressed as the mean ± SD. Student's ttest was used to examine statistically signiﬁcant
difference between the control and test groups.
*p < 0.05; **p < 0.01; ***p < 0.001.

The expression of NFE2L2 (NRF2 gene) in different
tumor type of clinical cohorts was retrieved from the
Oncomine (www.oncomine.org). The results
demonstrated that the expression of NRF2 is significantly up-regulated in tumor tissues compared to
normal tissues, especially in head and neck cancers
(Table 1). Western blot analysis shows abundant
expression of NRF2 in three different HNSCC cell
lines, particularly in HSC-3 cells (Fig. S1A). Phosphorylation at serine 40 (Ser40) was an important
mechanism of NRF2 stabilization and resulted in
NRF2/ARE pathway activation [15]. We noted that
the levels of serine 40 phosphorylated NRF2 was
signiﬁcantly increased in HSC-3 cells (Fig. S1A).
Furthermore, knockdown of NRF2 signiﬁcantly
reduced cell growth in HSC-3 cells (Fig. S1B). These
results indicated that NRF2 is unduly expressed and
associated with cell growth in HNSCC.
In order to discover novel and effective NRF2 inhibitors, we established a ARE-driven reporter cell
line from HSC-3 cells, named HSC3-ARE9, which
stably carried 9 repeats of consensus antioxidant
response element [14]. Using this sensitive and
efﬁcient cell-based screening platform, we screened
the SCREEN-WELL®REDOX Library, which

Table 1. Expression levels of NFE2L2 gene in cancer tissue versus normal in different cancer types.
Cancer type

Cohorta

Head-Neck
Colorectal
Leukemia

Talbot Head-Neck
Estilo Head-Neck
Gaedcke Colorectal
Haferlach Leukemia

Breast

Richardson Breast

a

Tongue SCC (n ¼ 31) versus Tongue (n ¼ 26)
Tongue SCC (n ¼ 31) versus Tongue (n ¼ 26)
Rectal Adenocarcinoma (n ¼ 65) versus Rectum (n ¼ 65)
Chronic Myelogenous Leukemia (n ¼ 76) versus
Peripheral Blood Mononuclear Cell (n ¼ 74)
Ductal Breast Carcinoma (n ¼ 40)
Versus Breast (n ¼ 7)

Fold
Change

p-value

1.645
1.644
1.228
1.150

0.006
0.005
3.67E-6
7.38E-4

1.111

0.002

Data regarding NRF2 mRNA expression in normal and tumor specimen was retrieved from ONCOMINE database (www.oncomine.org).

contains 84 compounds with pro-oxidant or antioxidant properties. As the result, we found 12 compounds, including resveratrol (A4), hydroquinone
(A5), ethylferulate (A7), t-BHQ (A11), apigenin (B11),
piceatannol (C2), ebselen (C5), curcumin (C7), noctyl caffeate (E6), carnosic acid (E12), tanshinone
IIA (F1), and bis-demethoxycurcumin (F5), which
exhibited NRF2/ARE-inducing properties with
greater than 2-fold increases in luciferase reporter
activities over control (Fig. 1A). We also identiﬁed 9
compounds, including b-lapachone (A3), idebenone
(A10), HBED (A12), hinokitiol (B3), U83836E (B8),
GERI-BP002A (B10), CDC (C4), gossypol (C9),
ciclopirox olamine (F7), which displayed signiﬁcant
NRF2/ARE-inhibiting properties with around or
greater than 2-fold reduction of luciferase reporter
activities compared with control (Fig. 1A).
In order to exclude potential NRF2 inhibitors that
may interfere with luciferase activity due to cytotoxicity, we analyzed cell viability under the same
conditions as the ARE-driven reporter analysis to
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further conﬁrm whether the effects of these compounds are actually due to inhibit the NRF2/ARE
pathway, not due to impaired cell viability. After the
test compound was treated at 25 mM for 24 h, the
selectivity index was calculated by dividing the fold
change of luciferase activity by the fold change of
cell viability. A lower selectivity index indicates that
the compound's inhibitory activity on the NRF2/
ARE pathway is higher than the inhibitory effect on
cytotoxicity. Among the 9 compounds selected in
primary screening, the selectivity indexes of idebenone and ciclopirox olamine are 0.86 and 0.77,
respectively. This result indicates that the effects of
these two compounds on NRF2 inhibition and
viability suppression could not be distinguished
(Table 2). In addition, the selectivity indexes of
lapachone, HBED, hinokitiol, U83836E, GERIBP002A, CDC, and gossypol are all less than 0.6.
Although lapachone showed the lowest selectivity
index, however, the cell viability dropped sharply to
11%, suggesting that the inhibitory effect of

Fig. 1. Screening of NRF2 modulators by using the stable ARE-driven reporter cell line, HSC3-ARE9. (A) The heat map shows the change of
luciferase activity after 24 h of incubation with 25 mM test compound in HSC3-ARE9 cells. (B) Doseeresponse effects of test compounds on AREdriven luciferase activity after 24 h of incubation. (C) The schematic illustration of the chemical structure of gossypol. (D) The comparison of basal
ARE-driven luciferase activity and cell viability of gossypol. HSC3-ARE9 cells were treated with the indicated concentration of gossypol. After 24 h,
the ARE-driven luciferase activity and cell viability were measured. (E) The effects of gossypol on t-BHQ-induced luciferase activity and cell viability.
HSC3-ARE9 cell were treated with the indicated concentration of gossypol in presence of 50 mM t-BHQ. After 24 h, ARE-driven luciferase activity
was measured and cell viability was evaluated by MTT assay.
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Table 2. The ARE-driven luciferase activity and cell viability of 25 mM test compounds in HSC3-ARE9 cells.
Well

Group

Luciferase Activity (% of control)

Cell Viability (% of control)

Selectivity Indexa

e
A3
A10
A12
B3
B8
B10
C4
C9
F7

Control
Lapachone
Idebenone
HBED
Hinokitiol
U83836E
GERI-BP002A
CDC
Gossypol
Ciclopirox olamine

100
2
55
58
31
30
16
35
19
61

100
11
64
98
83
59
47
90
48
79

1.00
0.18
0.86
0.59
0.37
0.51
0.34
0.39
0.40
0.77

a

The Selectivity Index was calculated by diving luciferase activity by cell viability.

lapachone on NRF2/ARE reporter activity may be
caused by rapid cytotoxicity (Table 2). Therefore, we
excluded idebenone, ciclopirox olamine, and lapachone, and selected 6 compounds (HBED, hinokitiol, U83836E, GERI-BP002A, CDC, gossypol) for
further validation of the dose effect. Among them,
we noticed that gossypol showed the most effective
effect in inhibiting ARE-driven luciferase activity
compared with other compounds (Fig. 1B).
3.2. Gossypol effectively inhibits NRF2/ARE
signaling pathway
Based on the above research, we noticed that
gossypol (Fig. 1C), a natural polyphenolic compound isolated from cotton plant [16], is the most
effective NRF2 inhibitor in SCREEN-WELL®
REDOX Library. To accurately determine the range
of efﬁcacious doses of gossypol, we preformed
luciferase reporter assay paralleled with cell
viability assay by using a two-fold serial dilution. As
shown in Fig. 1D, gossypol decreased ARE-driven
luciferase activity in a concentrationdependent
manner. The IC50 value of gossypol in suppressing
ARE-driven luciferase activity was approximately
1.56 mM. At this concentration, gossypol did not
affect cell viability. This result indicated that
gossypol inhibited luciferase activity certainly owing
to disturbing NRF2/ARE pathway, not because of
impairing cell viability. Next, we examined the effect
of gossypol on t-BHQ (a typical NRF2-activator)
induced ARE-driven luciferase activity. As shown in
Fig. 1E, a 2.5-fold increase in ARE-driven luciferase
activity was observed following treatment with
50 mM t-BHQ for 24 h. As consistent with basal AREluciferase activity, we noted that gossypol showed a
concentrationdependent effect to suppress tBHQinduced ARE-driven luciferase activity in
HSC3-ARE9 cells.
We further investigated the effects of gossypol on
the protein levels of NRF2 in HSC-3 cells by Western blot analysis. As shown in Fig. 2A, gossypol

reduced the levels of NRF2 protein in a
timedependent manner. Furthermore, treatment
with gossypol for 24 h, we found that as the concentration of gossypol increases, the total, cytoplasmic and nuclear NRF2 protein gradually
decreases (Fig. 2B). In order to conﬁrm the inhibitory effect of gossypol on the NRF2/ARE pathway,
we evaluated the expression of NRF2 regulatory
genes by RT-qPCR. After 24 h of treatment with
different concentrations of gossypol, the mRNA
levels of NRF2 downstream genes, such as NQO1,
HO1, AKR1C1/2/3, and PRDX1, decreased in a
concentration-dependent manner (Fig. 2C). These
results indicated that gossypol can indeed disrupt
the NRF2/ARE pathway, thereby blocking the transcription of NRF2 downstream genes.
3.3. Gossypol exhibits antitumor activity by
reducing the stability of NRF2 protein
Since gossypol reduces the expression level of
NRF2 protein in a time and dosedependent
manner (Fig. 2AeB), we further clariﬁed whether
the reduction of NRF2 protein level by gossypol is
related to changes in NRF2 mRNA. The result
demonstrated that treatment with different concentrations of gossypol for 24 h had no signiﬁcant
effect on the level of NFE2L2 (NRF2) mRNA (Fig. S2).
Therefore, we hypothesized that gossypol may
reduce the level of NRF2 protein by impairing the
stability of NRF2 protein. As shown in Fig. 2D, pretreatment of the proteasome inhibitor MG132 can
effectively restore the NRF2 protein level caused by
gossypol, indicating that gossypol promotes the
proteasome degradation of NRF2 protein.
To further evaluate the effects of gossypol on
anticancer effect of HNSCC cells, HSC-3 cells were
exposed to various concentrations of gossypol for 24,
48 or 72 h and the viable cells were determined by
staining with methylene blue. As shown in Fig. 2E,
the effect of gossypol on cell viability is not obvious
after 24 h of treatment. However, cell growth was
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Fig. 2. Gossypol effectively inhibits NRF2/ARE signaling pathway through impairing NRF2 protein stability and leads to reducing the
viability of HNSCC cells. (A) Time-dependent effects of 10 mM gossypol on the expression levels of NRF2 protein. (B) Dose-dependent effects of
gossypol on the expression levels of NRF2 protein after 24 h of treatment. b-Actin was used as the internal control. (C) The heat-map of NRF2regulated genes. HSC-3 cells were treated with various concentrations of gossypol for 24 h, and the mRNA levels of NRF2-regulated genes were
analyzed by real-time RT-PCR. (D) Proteasome inhibitor, MG132, restored NRF2 protein level after gossypol treatment. HSC-3 cells were pre-treated
with 25 mM MG132 for 30 min and then treated with or without 10 mM gossypol for additional 8 h. The level of NRF2 protein was determined by
Western blot assay. b-Actin was used as the internal control. (E) HSC-3 cells were treated with various concentrations of gossypol at different time
points. The percentage of viable cells was calculated compared to the control cells, and the IC50 values were calculated. (F) Gossypol signiﬁcantly
reduces colony forming ability in HSC-3 cells. Cells were seeded in 6-well plates with the indicated concentrations of gossypol for 24 h, then cells were
washed twice with PBS and continued to culture in gossypol-free medium for 10 days. The methylene blue dye assay has been used to measure the
number of colonies, and manual interpretation counts the colonies. Upper panel: the stained colonies were photographed; Bottom panel: the total
number of colonies in each group was counted. Data are presented as the mean ± S.D. from three independent experiments (**p < 0.01 vs. Control).
(G) Gossypol treatment induced cleaved PARP in HSC-3 cells. Cells were treated with 2.5, 5, 10 mM of gossypol for 24 h, the full length and cleaved
PARP were detected by Western blot analysis. b-Actin was used as the internal control.

markedly inhibited by gossypol in a time and
concentrationdependent manner after 48- and 72h treatment. The IC50 values of gossypol at 24, 48,
and 72 h were >10 mM, 5.8 mM and 3.6 mM,
respectively.
Clonogenic assay is an in vitro cell survival assay
based on the ability of a single cell to grow into a
colony, thus this assay could exactly distinguish
whether gossypol causes cell death or growth inhibition. As shown in (Fig. 2F), we found that a
gradual reduction of colony forming ability was
obviously observed with increasing concentrations
of gossypol, indicating that gossypol treatment
resulted in impaired HNSCC cell viability.
Furthermore, we detected the level of cleaved PARP,
a deﬁning feature of apoptosis, in HSC-3 cells after
treatment with gossypol for 24 h by Western blot

analysis (Fig. 2G). Even though a basal level of
cleaved PARP was observed in the control group,
gossypol treatment signiﬁcantly induced the cleavage of PARP in a concentrationdependent manner.
These ﬁndings suggested that gossypol induced
anti-cancer effect in part through apoptosis induction in HNSCC cells.
Over-activation of NRF2 has been considered to
play an important driver role for promoting tumor
progression and therapeutic resistance in non-small
cell lung cancers (NSCLC) [17]. Therefore, in addition to HNSCC cells, we also evaluated the anticancer effect of gossypol on the non-small cell lung
cancer (NSCLC) cell line NCIeH460. The results
showed that gossypol exhibited the dose-related
effect on cell viability of NCIeH460 cells with the
IC50 value of 2.6 mM (Fig. S3A). In addition, we also
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observed that gossypol signiﬁcantly reduced NRF2/
ARE downstream proteins in a concentrationdependent manner (Fig. S3B), suggesting that
gossypol is also an effective NRF2 inhibitor in
NSCLC cells.
3.4. Gossypol enhances the anticancer effect of
etoposide in topoisomerase II poison-resistant KB7D cancer cells by inhibiting the NRF2/MRP1 axis
We have previously demonstrated that enhanced
B-RAF-mediated NRF2 gene transcription and
HATs-mediated NRF2 protein acetylation contributes to multidrug resistance-associated protein 1
(MRP1/ABCC1)-mediated chemoresistance in acquired topoisomerase II poison-resistant KB-7D
cancer cells [8]. In addition, gene expression analysis of hundreds of cancer cell lines demonstrated
that etoposide sensitive cells showed higher ABCC1
(MRP1) mRNA level than etoposide resistant cells

(Fig. 3A). Therefore, we wondered whether gossypol
can reverse the resistance of topoisomerase II
poisonresistant KB-7D cells to etoposide. As
shown in Fig. 3B, gossypol decreases cell viability of
KB-7D cells in a dosedependent manner and the
IC50 value is 2.2 mM. Furthermore, we conﬁrmed
that gossypol can dose-dependently reduce NRF2
and MRP1 protein levels in KB-7D cells (Fig. 3C).
Compared with the group treated with etoposide
alone, the non-toxic concentration (0.625 and
1.25 mM) of gossypol signiﬁcantly increases the
sensitivity of KB-7D cells to etopoiside (Fig. 3D).
Markedly, the IC50 values of etoposide in KB-7D
cells decreased signiﬁcantly from 24.2 mM to 14.2 (in
combination with 0.625 mM gossypol) and 5.4 mM (in
combination with 1.25 mM gossypol), respectively
(Fig. 3D). These results suggested that gossypol
effectually re-sensitizes etoposide-resistant cells to
topoisomerase II poisons by reducing the protein
expression of NRF2 and MRP1.

Fig. 3. The effects of gossypol on the NRF2/MRP1 axis and etoposide sensitivity in etoposide-resistant KB-7D cells. (A) The expression levels
of MRP1 gene (ABCC1) in etoposide-resistant (left plot) and etoposide-sensitive (right plot) cancer cells were retrieved from ONCOMINE database.
(B) Drug sensitivity of gossypol in etoposide-resistant HNSCC KB-7D cells. Cells were treated with the indicated concentrations of gossypol for 72 h
and IC50 value was calculated. (C) Dose-dependent effect of gossypol on protein levels of NRF2 and MRP1. After treatment with the indicated
concentrations of gossypol for 24 h, the NRF2 and MRP1 protein levels were detected by Western blot analysis. b-Actin was used as the internal
control. (D) The combined effect of gossypol and etoposide on viability of KB-7D cells. Cells were co-treated with non-toxic concentrations of gossypol
(0.625 or 1.25 mM) and etoposide for 72 h. Cell viability was determined by methylene blue assays. (E) IC50 values was calculated when combination
of etoposide with non-toxic gossypol in KB-7D cells.

3.5. Gossypol may attenuate cisplatin resistance
through inhibiting NRF2/G6PD axis in head and
neck squamous cell carcinoma
Anomalistic activation of the NRF2/ARE signaling
pathway is believed to be the key mechanism that
causes cancer cells to develop resistance to platinum
drugs [7,17,18]. The discovery of effective anti-NRF2
therapeutics is a promising strategy for sensitizing
cancer cells to platinums [6,10,19]. We recently
identiﬁed that NRF2-mediated up-regulation of
glucose-6-phosphate dehydrogenase (G6PD) played
an important role to promote tumor progression in
HNSCC. Blocking the NRF2/G6PD axis can effectively induce the synthetic lethality of HNSCC cells
to cisplatin [13]. According to data retrieved from
ONCOMINE, we observed that the expression level
of G6PD mRNA is signiﬁcantly increased in
cisplatin-resistant cancer cells compared with
cisplatin-sensitive cancer cells (Fig. 4A). Therefore,
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the inhibitory potential of gossypol in NRF2/G6PD
axis was examined. The results demonstrated that
HNSCC cells treated with gossypol effectively
reduce the expression level of NRF2 and G6PD
protein in a concentration-dependent manner
(Fig. 4B). Therefore, we wondered whether gossypol
can re-sensitize the anti-cancer effect of cisplatin in
platinum resistant HNSCC cells.
To this end, cisplatin-resistant cells were established from HONE-1 cells (a representative HNSCC
cell line derived from nasopharyngeal carcinoma)
by exposure to increasing concentrations of
cisplatin, and named cis6 and cis15. Compared with
the parental HONE-1 cells, the IC50 values of the
two drug-resistant sublines cis6 and cis15 to
cisplatin were 7.4 and 18.8 times higher, respectively
(Fig. 4C). Moreover, the expression levels of total
and phospho-NRF2 proteins were also signiﬁcantly
higher in cis6 and cis15 cells than in parental
HONE-1 cell (Fig. 4D). The anti-cancer cytotoxic

Fig. 4. Gossypol enhances cisplatin sensitivity through inhibition of NRF2/G6PD axis in cisplatin resistant HNSCC cells. (A) The box plot of
G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right
plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment
with 0.625, 1.25, 2.5, and 5 mM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis.
b-Actin was used as the internal control. (C) The IC50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The
Resistance Index was calculated by dividing the IC50 value of cisplatin in resistant sub-line by the IC50 value of cisplatin in parental HONE-1 cell. (D)
Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. b-Actin was used as the internal control. (E ~ G) Cytotoxicity
effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 mM)
with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G:
cisplatin-resistant cis15 cells).
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Table 3. IC50 values for gossypol and cisplatin in HONE-1 and HONE-1 derived cisplatin-resistant cells.
Group

IC50 for Gossypol (mM)
IC50 for Cisplatin (mM)
Fold of chemo-sensitizationa

HONE-1 (parental)

Cisplatin alone
Cisplatin þ Gossypolb

1.32
2.02
1.55
1.3

cisplatin-resistant
cis6

cis15

1.13
18.1
12.2
1.5

0.89
42.5
23.4
1.8

a
The Fold of chemo-sensitization was calculated by diving the IC50 value of cisplatin alone group by cisplatin combined with gossypol
group.
b
The effects of gossypol on the cisplatin re-sensitization were assessed by combining the non-toxic concentration of gossypol (0.5 mM)
with various concentrations of cisplatin.

effect of gossypol is equal potent in HONE-1, cis6,
and cis15 with IC50 values of 0.89e1.32 mM (Table 3).
Compared with the group treated with cisplatin
alone, the non-toxic concentration of gossypol
(0.5 mM) can signiﬁcantly increase the sensitivity of
HONE-1, cis6, and cis15 cells to cisplatin
(Fig. 4EeG). Importantly, with the increase of
cisplatin resistance, the chemo-sensitization ability
of gossypol has been signiﬁcantly improved. As
shown in Table 3, the chemo-sensitization multiples
of gossypol were 1.3-, 1.5-, and 1.8-fold in HONE-1,
cis6 and cis15, respectively. These data indicated
that gossypol effectively enhances the anti-cancer
effect of cisplatin, especially in chemo-refractory
cancer cells.

4. Discussion
There is abundant evidence that the activation of
NRF2 can reduce carcinogens and oxidative stress
by inducing detoxiﬁcation and antioxidant proteins,
thereby inhibiting carcinogenesis, especially in its
early stages [20]. Chemically diverse chemopreventive agents are known to exhibit cytoprotective effects by activating the NRF2 signaling
pathway, many of which are dietary phytochemicals
[21]. Based on our ARE reporter screening platform
[14], we found that resveratrol, hydroquinone, ethylferulate, t-BHQ, apigenin, piceatannol, ebselen,
curcumin, n-octyl caffeate, carnosic acid, tanshinone
IIA, and bis-demethoxycurcumin exhibited signiﬁcant NRF2/ARE-activating capacity with more than
a two-fold increase of luciferase activity (Fig. 1).
Indeed, all of these compounds were reported to
activate NRF2/ARE pathway [22e24]. Among them,
t-BHQ, resveratrol, and curcumin were deemed as
the typical NRF2 activators [24]. These results indicated that our ARE reporter screening platform can
fully verify previous publications, showing that this
platform has excellent accuracy and credibility for
discovery of NRF2 modulators.
Considering the role of NRF2 in regulating a
battery of genes that act to detoxify anti-cancer

drugs, attenuate drug-induced oxidative stress, or
induce drug efﬂux, it is not surprise to note that
NRF2/ARE pathway also plays an important role in
developing cancer chemo-resistance [4,5]. Therefore, we aimed to identify novel NRF2 inhibitors as
adjuvant chemotherapeutic agents. As the results,
we found that HBED, hinokitiol, U83836E, GERIBP002A, CDC, and gossypol were potential NRF2
inhibitors. Among them, gossypol exhibited the
highest ARE-driven luciferase inhibitory activity,
and the second most effective compound was
hinokitiol (Fig. 1). Hinokitiol is a known NRF2 inhibitor [25]. Of note, HBED, U83836E, GERIBP002A, CDC and gossypol have never been reported to have NRF2 inhibitory activity, and they
were ﬁrst clariﬁed in this study.
Gossypol is a lipid-soluble and non-steroidal
polyphenolic compound that naturally occurs in the
cotton plant (genus Gossypium) and the portia tree
(Thespesia populnea (L.) Sol. ex Corr^
ea) [26].
Gossypol and its derivatives was known to have
potential anti-tumor effects [26]. Among them, the
anti-apoptotic protein Bcl-2 and Bcl-xL is the most
striking anti-tumor mechanism of gossypol and its
derivatives [26,27]. Among them, AT101, the R-()
enantiomer of gossypol acetic acid, has been studied
in clinical for treatment of gastroesophageal carcinoma, advanced adrenal cortical carcinoma, prostate cancer, refractory metastatic breast cancer, and
small cell lung cancer [26]. The combination of
gossypol with other anti-cancer agents, such as
topotecan [28], androgen deprivation therapy [29],
docetaxel [30], and trastuzumab [31], have been also
studied in clinical. AT101 has been applied to clinical use in the treatment of cancer in China [26]. In
addition to induce cell death, gossypol has been also
reported to diminish the epithelial-to-mesenchymal
transition and metastatic potential of cancer cells by
suppression of FAK signaling pathway and key
molecules involved in EMT, such as N-cadherin,
ﬁbronectin and vimentin [32,33]. Gossypol also
signiﬁcantly inhibited the expression level or enzymatic activity of extracellular matrix-degrading

proteases, such as Urokinase-type plasminogen
activator (uPA) and matrix metallopeptidase 2
(MMP-2), thereby reducing the ability of cancer cells
to metastasize [32,33].
We ﬁrst time revealed that gossypol was a novel
and potential NRF2 inhibitor. It not only suppressed
basal ARE-driven luciferase activity but also
inhibited t-BHQ-induced ARE-driven luciferase activity in HNSCC cells. Further studies demonstrated
that gossypol signiﬁcantly suppressed the expression levels of NRF2 protein and NRF2-regulated
cytoprotective genes in a concentration- and timedependent manners (Fig. 2AeC). We explored the
potential mechanism of gossypol inhibiting the level
of NRF2 protein, and found that gossypol reduced
the expression levels of NRF2 protein by inducing
protein degradation without affecting the level of
NRF2 mRNA (Fig. 2D & S2). Interestingly, we noted
that under short-term treatment (24 h), gossypol
signiﬁcantly inhibited NRF2 activity without
affecting cell survival. Once the treatment time was
extended (48 or 72 h), gossypol signiﬁcantly reduced
the viability of cancer cells (Fig. 2EeF & S3A).
Gossypol has been reported to induce both
apoptosis and autophagic cell death in cancer cells
[34e36]. In the present study, we observed that
treatment with gossypol signiﬁcantly induced
apoptosis (Fig. 2G). In addition, we also found that
gossypol caused the conversion of LC3-I to LC3-II,
an autophagy marker, in HSC-3 cells (Fig. S4),
suggesting that gossypol may also trigger autophagy
in HNSCC cells. However, the role of gossypolinduced autophagy in HNSCC cells whether triggering autophagic cell death remains to be elucidated. Furthermore, the cell cycle analysis
demonstrated that gossypol strikingly induced S
and G2/M phases arrest in the time- and dosedependent manners (Fig. S5A-B). The obtained results adumbrated that gossypol-induced suppression of NRF2/ARE pathway may act on the S/G2/M
phases and then reduces the viability of cancer cells.
A previous study demonstrated that apogossypolone (ApoG2), a derivate of gossypol, stimulated cell
cycle arrest at S phase through downregulation of
proto-oncogene c-MYC and G1/S checkpoints
cyclin D1/cyclin E and induction of tumor suppressor p21 proteins [37]. The molecular mechanism
underlying the cell cycle perturbation and NRF2
inhibition by gossypol in HNSCC cells remains
further clariﬁcations.
It has been reported that excessive activation of
NRF2/ARE pathway has brought great beneﬁts for
tumor progression [3], and prolonged activation of
NRF2/ARE signal pathway confers therapeutic
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resistance of cancer cells through inductions of
antioxidant proteins, metabolizing/detoxifying enzymes, and drug-efﬂux transporters, etc. [4,5,7,8].
Therefore, inhibition of NRF2 is not only a potential
treatment to eradicate tumors but also a chemosensitization strategy to reverse chemoresistance
[6e8,10,13]. For instance, ERK-stimulated hyperactivation of the NRF2/ARE pathway played an
important role in acquired resistance against
tamoxifen in human breast cancer cells [38]. Epicatechin gallate (EGCG), the major catechin found
in green tea, which was found that exhibited antiproliferative activity in patient-derived triple-negative breast cancer xenograft mouse model [39],
strikingly suppressed NRF2/ARE pathway and efﬁciently re-sensitized tamoxifen-resistant breast
cancer cells [40]. Furthermore, etoposide, a topoisomerase II poison, is a widely used chemotherapeutic agent. We previously established an
etoposide-resistant cell line KB-7D and found that
activation of NRF2/multidrug resistance protein 1
(MRP1/ABCC1) axis caused acquired resistance to
topoisomerase II poisons [8]. It was worth noting
that the combination of etoposide and gossypol can
signiﬁcantly improve the therapeutic efﬁcacy of
etoposide and reverse drug resistance by reduction
of the expression levels of NRF2 and MRP1 proteins
in etoposide-resistant KB-7D cells (Fig. 3). These
results indicated that gossypol may have potential to
enhance therapeutic efﬁcacy of topoisomerase II
poison-refractory tumors clinically.
Platinum-based chemotherapeutic drugs, such as
cisplatin, carboplatin, and oxaliplatin, are the most
powerful and widely used anti-cancer agents [41].
Although platinum-based chemotherapy remains
the cornerstone for cancer treatment, but most patients experienced relapse and further developed
platinum resistance [41]. We and others previous
studies demonstrated that NRF2 promotes the
resistance of cancer cells to platinum-based
chemotherapy by inducing the antioxidant proteins
and metabolizing/detoxifying enzymes [5,7,18].
More recently, we revealed that inhibiting NRF2mediated glucose-6-phosphate dehydrogenase
(G6PD) expression stimulated the synthetic lethality
with cisplatin in HNSCC cells [13], indicating that
NRF2-mediated metabolic reprogramming also
contributes to cisplatin resistance. In this study, we
ﬁrst identiﬁed that gossypol strikingly suppressed
both NRF2 and G6PD protein levels in a concentration-dependent manner. Similar to the inhibitory
effect on the protein level, we further veriﬁed that
gossypol signiﬁcantly reduced the expression of
G6PD mRNA (Fig.S6). These results implied that
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gossypol may suppress G6PD through inhibiting
NRF2-mediated G6PD gene transactivation. Therefore, we inferred that gossypol inhibits the NRF2/
G6PD axis as one of the mechanisms to alleviate
cisplatin resistance in HNSCC cells. To further
simulate the clinical treatment conditions, we
established two cisplatin resistant cell lines cis6 and
cis15 from HONE-1 cells for further study. As
compared to HONE-1 cells, cis6 and cis15 cells
showed 7.4- and 18.8-fold resistance to cisplatin,
respectively, and resistant cells also expressed
higher level of total NRF2 and phospho-NRF2 than
parental cells (Fig. 4AeD). Unlike with cisplatin,
gossypol was equal potent between parental and
resistant cells with IC50 values approximately 1 mM.
Notably, combination of non-toxic concentration of
gossypol markedly increased cisplatin sensitivity
thereby reduced the IC50 values of cisplatin in
HONE-1, cis6, and cis15 cells (Fig. 4EeG & Table 3).
Importantly, as the resistance of cells to cisplatin
increases, gossypol had a better ability to sensitize
cisplatin (Table 3). Previous studies have shown that
gossypol enhanced the sensitivity of cancer cells to
cisplatin through inhibiting anti-apoptotic Bcl-2
family proteins, blocking APE1-mediated IL-6/
STAT3 signaling, and up-regulating pro-apoptotic
molecule Smac [26,27,42]. Nevertheless, our
research clearly demonstrated that in addition to the
aforementioned regulatory mechanisms, the inhibition of NRF2 by gossypol was a novel and
important mechanism for chemo-sensitization and
drug resistance reversal in cisplatin resistant cells.
In conclusion, we identiﬁed that gossypol was a
novel NRF2/ARE inhibitor. This was the ﬁrst study
to corroborate that gossypol reduces the stability of
NRF2 protein and leads to inhibition of NRF2mediated transcriptional signature. Importantly,
gossypol not only inhibited growth of cancer cells,
but also enhanced the therapeutic effects of etoposide and cisplatin in drug-resistant cancer cells by
inhibiting the NRF2/MRP1 and NRF2/G6PD axis,
respectively. These results suggested that blockade
of NRF2 signal by gossypol may have the potential
to enhance therapeutic efﬁcacy of chemo-refractory
tumors in the clinic.
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Appendix.
Supplementary materials and methods
Chemical reagents. The SCREEN-WELL® REDOX
Library (BML-2835, Version 1.0) was obtained from
Enzo Life Sciences (NY., USA). Other chemicals
were purchased from SigmaeAldrich (Saint Louis,
MO., USA) unless otherwise stated. Dulbecco's
Modiﬁed Eagle Medium (DMEM), Minimum
Essential
Media
(MEM),
Ham's
F-12,
100  Penicillin-Streptomycin-Glutamine solution,
fetal bovine serum (FBS), trypsin, and G418 were
purchased from Gibco-Thermo Fisher Scientiﬁc
(MA., USA). The primary antibodies used in this
study were listed in Table S1.
RNA extraction and real-time PCR. Total RNA
were obtained from cells by using the NucleoSpin
RNA puriﬁcation kit (740955, MachereyeNagel,
Düren, Germany), and then the cDNA was synthesized from equal amounts (2 mg) of total RNA using
SuperScriptTM III Reverse Transcriptase (12574026,
Invitrogen, MA, USA). Real-time PCR was performed under the following conditions: an initial
denaturing cycle at 95  C for 3 min, followed by 40
cycles of ampliﬁcation consisting of denaturation at
95  C for 3 s, annealing at 60  C for 30 s. An extend
program as following: 95  C for 15 s, 60  C for 1 min,
and 95  C for 15 s was added after the last cycle for
melting curve stage. The forward and reverse
primer sequences used to amplify each target gene
were listed in Table S2. The changes of NRF2,
NQO1, HO1, AKR1C1, AKR1C2, AKR1C3 and
PRDX1 mRNA levels were expressed as fold to
control after normalization to RPLP0.
Western blot analysis. Western blot analysis was
performed on total protein isolated from cells. Total
protein was extracted, and protein concentration was
determined by the Bradford assay (#5000006, Bio-Rad
Laboratories, CA, USA). Equal amounts (40 mg) of
total protein were separated by 10% SDS-PAGE with
a loading buffer (100 mM TriseHCl, pH 6.8, 4% SDS,

p-NRF2
(S40)
β-Acn

HSC-3

SCC15

120

Growth Index
(% of siControl)

t-NRF2

Supplementary ﬁgures

(B)
TW2.6

(A)

20% glycerol, 0.2% bromophenol blue, and 10% bmercaptoethanol). The separated protein in SDSPAGE was transferred to PVDF membrane (Millipore
Co., Bedford, MA). After blocking with 5% skim milk
in 1  PBST for 1 h at room temperature, the membrane was incubated with primary antibody at 4  C
for overnight. After washing three times for 10 min
each with TBST, the membrane was incubated with
the secondary antibody for 1 h at room temperature.
The immunoreactive bands were visualized by using
WesternBright ECL (R-03031, Advansta, CA, USA).
All primary antibodies were used at dilutions of
1:500e2000 and listed in Table S1. Donkey anti-rabbit
IgG and donkey anti-mouse IgG conjugated with
horseradish peroxidase were used as the secondary
antibody at a dilution of 1:5000.
Cell cycle analysis. For analysis of the cell cycle
distribution, HSC-3 cells were incubated with
various concentrations of gossypol (0, 2.5, and 5 mM)
for 24 and 48 h, and then cells were collected by
centrifugation. The harvested cell pellets were ﬁxed
in 80% ethanol (dissolved in 1  PBS, pH 7.4) and
stored at 20  C at least 2 h. For analysis, cell pellets
were washed with cold 1  PBS (pH 7.4), incubated
at 4  C for 30 min with 50 mg/ml RNase A (Sigma),
and then stained with 50 mg/ml propidium iodide
(Sigma) in 1  PBS. Cell cycle proﬁles and distributions were determined by ﬂow cytometry analysis
of 104 cells using the CELLQuest program on a
FACS Calibur ﬂow cytometer (BectoneDickinson,
San Jose, CA). Clumped cells were excluded from
the cell cycle distribution analysis by gating.
Gene expression analysis from Oncomine database. Data regarding NRF2 mRNA expression in
normal and tumor specimen, and ABCC1 (MRP1)
and G6PD mRNA expression in drug-resistant and
drug-sensitive cancer cell lines was retrieved from
ONCOMINE database (www.oncomine.org).

HSC-3

90

***

60
30
0

siControl

siNRF2

Fig. S1. NRF2 is unduly expressed and associated with cell growth in HNSCC. (A) The levels of total NRF2 (t-NRF2) and phospo-NRF2 (Ser40)
proteins were detected by western blotting in HNSCC cell lines. b-Actin was used as the internal control. (B) The effect of NRF2-knockdown on the
viability of HSC-3 cells. Data are presented as the mean ± S.D. from three independent experiments (***p < 0.001 vs. siControl).
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Fig. S2. Gossypol does not impair NRF2 mRNA level in HNSCC
cells. The expression levels of NRF2 mRNA did not change after
gossypol treatment. The levels of NRF2 mRNA were detected by RTqPCR after incubation with 2.5, 5, 10 mM gossypol for 24 h in HSC3 cells.

Fig. S4. Gossypol induces the autophagy in HSC-3 cells. HSC-3 cells
were treated with the indicated concentration of gossypol. After 24 h,
cells were lysed and the levels of LC3-I and LC3-II were determined
were detected by western blotting. The b-actin was used as the loading
control. The cells treated with 50 mM chloroquine (CQ) for 24 h was
used as a positive control.
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Fig. S5. Gossypol induces cell cycle arrest at the G2/M phase in
HNSCC cells. HSC-3 cells were incubated with various concentrations
of gossypol (0, 2.5, and 5 mM) for 24 and 48 h, and the cell cycle distribution was determined by ﬂow cytometry followed by PI staining. Bar
graphs show the percentages of HSC-3 cells in G0/G1, S, and G2/M
phases after treatment with gossypol for 24 h (A) and 48 h (B),
respectively.
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Fig. S3. Effects of gossypol on cell viability of non-small cell lung
cancer cell line NCIeH460. (A) Doseeresponse curve for viability
using methylene blue assay in NCIeH460 cells exposed to gossypol for
72 h and the IC50 value was calculated. The percentage of viable cells
was calculated compared to the control cells. (B) Dose-dependent effects
of gossypol on protein levels of NRF2 and NRF2-downstream proteins,
such as AKR1C2 and PRDX1. NCIeH460 cells were incubated with the
indicated concentrations of gossypol for 24 h. The changes of NRF2,
AKR1C2, and PRDX1 protein levels were evaluated by western blot
assay. b-Actin was used as the internal control.
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Fig. S6. Gossypol reduces G6PD mRNA levels in HNSCC cells. The
expression levels of G6PD mRNA were decreased after gossypol treatment. The levels of G6PD mRNA were detected by RT-qPCR after incubation with 0, 2.5, 5, 10 mM gossypol for 24 h in HSC-3 cells.
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Supplementary tables

Table S1. Antibody list
Antibody

Assay

Host

Information

a-Tubulin
b-Actin
AKR1C1
G6PD
Lamin B1
MRP1/ABCC1
NRF2
p-NRF2(S40)
NQO1
PARP
PRDX1

Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot
Immunoblot

mouse
mouse
mouse
rabbit
mouse
rabbit
rabbit
rabbit
mouse
rabbit
rabbit

GTX628802 (GeneTex)
GTX109639 (GeneTex)
H00001645-A01 (Abnova)
8866S (Cell Signaling Technology)
ab20396 (Abcam)
72202S (Cell Signaling Technology)
ab62352 (Abcam)
ab76026 (Abcam)
3187S (Cell Signaling Technology)
GTX100573 (GeneTex)
ARP48454_P050 (Aviva Systems Biology)

Table S2. Primers used for quantitative real-time RT-PCR
Gene

Sequence

hAKR1C1

FP
RP
FP
RP
FP
RP
FP
RP
FP
RP
FP
RP
FP
RP
FP
RP
FP
RP

hAKR1C2
hAKR1C3
hG6PD
hHO-1
hNRF2
hNQO1
hPRDX1
hRPLP0

CATGCCTGTCCTGGGATTT
AGAATCAATATGGCGGAAG
GCAGCGCATCAGACAGAA
CAAGGGTCAAATATCGCACA
CATTGGGGTGTCAAACTTCA
CCGGTTGAAATACGGATGAC
TGACCTGGCCAAGAAGAAGA
CAAAGAAGTCCTCCAGCTTG
TTCAGAAGGGCCAGGTGA
CCTCAAGGGCCACATAGAT
CAGCGACGGAAAGAGTATGA
TGGGCAACCTGGGAGTAG
ATGTATGACAAAGGACCCTTCC
TCCCTTGCAGAGAGTACATGG
CACTGACAAACATGGGGAAGT
TTTGCTCTTTTGGACATCAGG
TGGTCATCCAGCAGGTGTTCGA
ACAGACACTGGCAACATTGCGG

Accession no.

Product size (bp)

NM_001353.6

109

NM_001354.6

104

NM_003739.6

112

NM_000402.4

185

NM_002133.3

78

NM_006164.5

200

NM_000903.3

88

NM_002574.4

82

NM_001002

119
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